Pharvaris (NASDAQ:PHVS) President Peng Lu Sells 15,000 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of Pharvaris stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $40.68, for a total value of $610,200.00. Following the completion of the sale, the president directly owned 65,179 shares in the company, valued at approximately $2,651,481.72. The trade was a 18.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Peng Lu also recently made the following trade(s):

• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The stock was sold at an average price of $34.00, for a total value of $10,200.00.

Pharvaris Price Performance

Shares of NASDAQ PHVS traded up $0.03 during midday trading on Wednesday, reaching $37.87. 472,007 shares of the stock traded hands, compared to its average volume of 375,401. The stock has a market capitalization of $2.48 billion, a PE ratio of -12.42 and a beta of -2.33. Pharvaris N.V. has a one year low of $20.65 and a one year high of $43.25. The company’s 50 day moving average is $34.86 and its 200 day moving average is $31.20.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, equities analysts forecast that Pharvaris N.V. will post -3.15 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Several hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System increased its stake in Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after purchasing an additional 520 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Quantbot Technologies LP bought a new position in shares of Pharvaris in the second quarter worth about $41,000. Public Employees Retirement System of Ohio increased its stake in Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after buying an additional 1,300 shares during the period. Finally, Legal & General Group Plc increased its stake in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PHVS shares. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday. Morgan Stanley reissued an “overweight” rating and set a $62.00 price objective on shares of Pharvaris in a research note on Wednesday. Royal Bank Of Canada upped their price objective on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday. Citizens Jmp raised their price objective on Pharvaris from $75.00 to $79.00 and gave the company a “market outperform” rating in a research note on Wednesday. Finally, Guggenheim lifted their target price on Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.21.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Positive Phase 3 results support the stock: Pharvaris reported that the CHAPTER-3 pivotal study of deucrictibant XR met its primary endpoint and all secondary efficacy endpoints with statistically significant and clinically meaningful results. The oral therapy reduced HAE attacks in the prophylaxis setting, and the results are expected to support marketing-authorization applications beginning in the first half of 2027. Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study
• Positive Sentiment: Analysts raised their valuation expectations: Royal Bank of Canada lifted its price target to $62 from $52 and maintained an “outperform” rating. Citizens JMP raised its target to $79 from $75 and retained a “market outperform” rating. These targets imply substantial upside and reflect increased confidence in deucrictibant XR’s clinical and commercial potential. RBC Raises Price Target on Pharvaris
• Positive Sentiment: Broad analyst support continues: HC Wainwright reaffirmed its “buy” rating with a $60 target, while Wedbush maintained “outperform” with a $42 target. The upgrades and reiterations indicate that the clinical win is being incorporated into forecasts and valuation models.
• Neutral Sentiment: Key risks remain: RBC continued to classify Pharvaris as a speculative investment. The company remains loss-making, and the drug still faces regulatory review, manufacturing, launch-execution and competitive risks before it can generate commercial revenue.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.